1887
6 - Al-Bayan University Scientific Conference
  • ISSN: 1999-7086
  • E-ISSN: 1999-7094

ملخص

Solid oral dosage forms are widely used in the management of chronic diseases. They are preferred due to their ease of administration, affordability, stability, and accuracy in dose measurement. However, there are challenges with oral delivery due to a number of physiological and metabolic barriers that may impair therapeutic efficacy. Difficulties such as limited water solubility and biological membrane translocation can have a major impact on how well a drug is absorbed. The complexity of developing an oral dosage form is further compounded by considerations such as the drug stability, the impact of gastrointestinal pH, and interactions with metabolic enzymes and biological efflux mechanisms. One of the most important pharmacokinetic indicators of a drug's ability to achieve systemic availability after absorption is bioavailability. It is controlled by how well the drug dissolves and how well it passes through physiological barriers. The purpose of bilosomes, vesicular carriers composed of bile salts and nonionic surfactants, is to improve the administration of vaccinations and drugs. The gastrointestinal tract (GIT) can efficiently transport a range of pharmacological drugs, such as those with antibacterial, antifungal, and antiparasitic capabilities, as well as vaccines and bioactive molecules that target infectious organisms, due to their stability and malleability. For oral medications, bilosomal formulations exhibit higher delivery efficacy due to the complex and hostile environment of the GIT. This research evaluates the potential of bilosomes as a delivery system and highlights how they could be used to administer medications for diseases and viruses that affect the GIT.

Loading

جارٍ تحميل قياسات المقالة...

/content/journals/10.5339/jemtac.2024.absc.17
٢٠٢٤-١٠-١٤
٢٠٢٥-٠٤-٠٩
The full text of this item is not currently available.

References

  1. Zarenezhad E, Marzi M, Abdulabbas HT, Jasim SA, Kouhpayeh SA, Barbaresi S, et al. Bilosomes as Nanocarriers for the drug and vaccine delivery against gastrointestinal infections: Opportunities and challenges. J Funct Biomater. 2023 Sep 1;14(9):453. doi: 10.3390/jfb14090453.
    [Google الباحث العلمي]
  2. Nemati M, Fathi-Azarbayjani A, Al-Salami H, Roshani Asl E, Rasmi Y. Bile acid-based advanced drug delivery systems, bilosomes and micelles as novel carriers for therapeutics. Cell Biochem Funct. 2022 Aug;40(6):623–35. doi: 10.1002/cbf.3732.
    [Google الباحث العلمي]
  3. Saifi Z, Rizwanullah M, Mir SR, Amin S. Bilosomes nanocarriers for improved oral bioavailability of acyclovir: A complete characterization through in vitro, ex-vivo and in vivo assessment. J Drug Deliv Sci Technol. 2020 Jun;57:101634. doi: 10.1016/j.jddst.2020.101634.
    [Google الباحث العلمي]
  4. Kulkarni S, Prabhakar B, Shende P. Stabilization of lipid vesicles: Upcoming strategic insights for product development. J Mol Liquids. 2022;348(S1):118430. doi: 10.1016/j.molliq.2021.118430.
    [Google الباحث العلمي]
  5. Shanbhag P, Lande S, Chandra R, Rane D. Bilosomes: Superior vesicular carriers. Curr Drug Therapy. 2020;15(4):312–20. doi: 10.2174/1574885514666190917145510.
    [Google الباحث العلمي]
  6. Shukla A, Mishra V, Kesharwani P. Bilosomes in the context of oral immunization: Development, challenges and opportunities. Drug Discov Today. 2016 Jun;21(6):888–99. doi: 10.1016/j.drudis.2016.03.013.
    [Google الباحث العلمي]
  7. Elia RV, Woods S, Butcher W, McGahon J, Khadke S, Perrie Y, et al. Exploitation of the bilosome platform technology to formulate antibiotics and enhance efficacy of melioidosis treatments. J Control Release. 2019 Mar 28:298:202–12. doi: 10.1016/j.jconrel.2019.02.002.
    [Google الباحث العلمي]
  8. Zafar A, Alruwaili NK, Imam SS, Alsaidan OA, Yasir M, Ghoneim MM, et al. Development and evaluation of luteolin loaded pegylated bilosome: optimization, in vitro characterization, and cytotoxicity study. Drug Deliv. 2021 Dec;28(1):2562–2573. doi: 10.1080/10717544.2021.2008055.
    [Google الباحث العلمي]
  9. Zafar A, Alsaidan OA, Imam SS, Yasir M, Alharbi KS, Khalid M. Formulation and evaluation of moxifloxacin loaded bilosomes in-situ gel: Optimization to antibacterial evaluation. Gels. 2022 Jul 4;8(7):418. doi: 10.3390/gels8070418.
    [Google الباحث العلمي]
  10. Binsuwaidan R, Sultan AA, Negm WA, Attallah NGM, Alqahtani MJ, Hussein IA, et al. Bilosomes as nanoplatform for oral delivery and modulated in vivo antimicrobial activity of lycopene. Pharmaceuticals (Basel). 2022 Aug 24;15(9):1043. doi: 10.3390/ph15091043.
    [Google الباحث العلمي]
  11. Taher S, Ahmed Z, Al-Kinani K, Alwan Z. Solid lipid nanoparticles as a promising approach for delivery of anticancer agents: Review article. Mil Med Sci Lett (Voj Zdrav Listy). 2022;91(3):197–207. doi: 10.31482/mmsl.2021.042.
    [Google الباحث العلمي]
  12. Abdulqader A, Ayash N. Preparation and characterization of posaconazole as a nano-micelle using d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS). Iraqi J Pharm Sci. 2023;32:26–32. doi: 10.31351/vol32issSuppl.pp26-32.
    [Google الباحث العلمي]
  13. Niu M, Lu Y, Hovgaard L, Guan P, Tan Y, Lian R, et al. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: The effect of cholate type, particle size and administered dose. Eur J Pharm Biopharm. 2012 Jun;81(2):265–72. doi: 10.1016/j.ejpb.2012.02.009.
    [Google الباحث العلمي]
  14. Aburahma MH. Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide/protein-based therapeutics or vaccines. Drug Deliv. 2016 Jul;23(6):1847–67. doi: 10.3109/10717544.2014.976892.
    [Google الباحث العلمي]
  15. Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery—an overview. Acta Pharm Sin B. 2011;1(4):208–19. doi: 10.1016/j.apsb.2011.09.002.
    [Google الباحث العلمي]
  16. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998 Oct;172(1–2):33–70. doi: 10.1016/S0378-5173(98)00169-0.
    [Google الباحث العلمي]
  17. Ruckmani K, Sankar V. Formulation and optimization of zidovudine niosomes. AAPS PharmSciTech. 2010;11(3):1119–27. doi: 10.1208/s12249-010-9480-2.
    [Google الباحث العلمي]
  18. Ahmad J, Singhal M, Amin S, Rizwanullah M, Akhter S, Kamal AM, et al. Bile salt stabilized vesicles (Bilosomes): A novel nano-pharmaceutical design for oral delivery of proteins and peptides. Curr Pharm Des. 2017;23(11):1575–88. doi: 10.2174/1381612823666170124111142.
    [Google الباحث العلمي]
  19. Muhesen RA, Ayash N. Formulation and characterization of olmesartan medoxomil as a nanoparticle. Res J Pharm Technol. 2023 Jul;16(7):1–7. doi: 10.52711/0974-360X.2023.00547.
    [Google الباحث العلمي]
  20. Nemr AA, El-Mahrouk GM, Badie HA. Hyaluronic acid-enriched bilosomes: An approach to enhance ocular delivery of agomelatine via D-optimal design: formulation, in vitro characterization, and in vivo pharmacodynamic evaluation in rabbits. Drug Deliv. 2022 Dec;29(1):2343–56. doi: 10.1080/10717544.2022.2100513.
    [Google الباحث العلمي]
  21. Edhari GH, Al Gawhari FJ. Study the effect of formulation variables on preparation of nisoldipine loaded nano bilosomes. Pharm Sci. 2023;32:271–82. doi: 10.31351/vol32issSuppl.pp271-282.
    [Google الباحث العلمي]
  22. Wang C, Siriwardane DA, Jiang W, Mudalige T. Quantitative analysis of cholesterol oxidation products and desmosterol in parenteral liposomal pharmaceutical formulations. Int J Pharm. 2019 Oct 5:569:118576. doi: 10.1016/j.ijpharm.2019.118576.
    [Google الباحث العلمي]
  23. Smail SS, Ghareeb MM, Omer HK, Al-Kinani AA, Alany RG. Studies on surfactants, cosurfactants, and oils for prospective use in formulation of ketorolac tromethamine ophthalmic nanoemulsions. Pharmaceutics. 2021 Mar 30;13(4):467. doi: 10.3390/pharmaceutics13040467.
    [Google الباحث العلمي]
  24. Kauslya A, Borawake PD, Shinde JV, Chavan RS. Niosomes: A novel carrier drug delivery system. J Drug Deliv Ther. 2021 Jan–Feb;11(1):162–170. doi: 10.22270/jddt.v11i1.4479.
    [Google الباحث العلمي]
  25. Alruwaili NK, Zafar A, Alsaidan OA, Yasir M, Mostafa EM, Alnomasy SF, et al. Development of surface modified bilosomes for the oral delivery of quercetin: Optimization, characterization in-vitro antioxidant, antimicrobial, and cytotoxicity study. Drug Deliv. 2022 Dec;29(1):3035–50. doi: 10.1080/10717544.2022.2122634.
    [Google الباحث العلمي]
  26. Dopazo GA, Martinez-Castillo C, Alonso-Ferrer M, Mejuto JC. Modeling the behavior of amphiphilic aqueous solutions. In: Mazzeo PL, Spagnolo P (eds.), Deep Learning Applications. IntechOpen; 2021.
    [Google الباحث العلمي]
  27. Waglewska E, Pucek-Kaczmarek A, Bazylińska U. Novel surface-modified bilosomes as functional and biocompatible nanocarriers of hybrid compounds. Nanomaterials (Basel). 2020 Dec 10;10(12):2472. doi: 10.3390/nano10122472.
    [Google الباحث العلمي]
  28. Abdelkader H, Alani AWG, Alany RG. Recent advances in non-ionic surfactant vesicles (niosomes): Self-assembly, fabrication, characterization, drug delivery applications and limitations. Drug Deliv. 2014 Mar;21(2):87–100. doi: 10.3109/10717544.2013.838077.
    [Google الباحث العلمي]
  29. Witika BA, Bassey KE, Demana PH, Siwe-Noundou X, Poka MS. Current advances in specialised niosomal drug delivery: Manufacture, characterization and drug delivery applications. Int J Mol Sci. 2022 Sep;23(17):9668. doi: 10.3390/ijms23179668.
    [Google الباحث العلمي]
  30. Aziz DE, Abdelbary AA, Elassasy AI. Investigating superiority of novel bilosomes over niosomes in the transdermal delivery of diacerein: In vitro characterization, ex vivo permeation and in vivo skin deposition study. J Liposome Res. 2019 Mar;29(1):73–85. doi: 10.1080/08982104.2018.1430831.
    [Google الباحث العلمي]
  31. Naji GH, Al Gawhari FJ. Evaluation of types and concentration of bile salts impact on physical properties of nisoldipine-loaded bilosomes. Pharmacia. 2024;71:1–7. doi: 10.3897/pharmacia.71.e116917.
    [Google الباحث العلمي]
  32. Khalil RM, Abdelbary A, Kocova El-Arini S, Basha M, El-Hashemy HA. Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride: In vitro and ex vivo optimization. J Liposome Res. 2019 Jun;29(2):171–82. doi: 10.1080/08982104.2018.1524482.
    [Google الباحث العلمي]
  33. Xu W, Yu X, Liang R, Liu S, Tian Q, Deng R, et al. Generation of polymer nanocapsules via a membrane-extrusion emulsification approach. Mater Lett. 2012 Jun 15;77:96–9. doi: 10.1016/j.matlet.2012.03.004.
    [Google الباحث العلمي]
  34. Jana SS, Lad MD, Subramanian S. Bilosomes as non-invasive drug delivery system. Int J Creative Res Thoughts. 2022 Apr;10(4):d854–69.
    [Google الباحث العلمي]
  35. Elnaggar YSR. Multifaceted applications of bile salts in pharmacy: An emphasis on nanomedicine. Int J Nanomed. 2015 Jun 12;10:3955–71. doi: 10.2147/IJN.S82558.
    [Google الباحث العلمي]
  36. Zafar A, Alruwaili NK, Imam SS, Hadal Alotaibi N, Alharbi KS, Afzal M, et al. Bioactive apigenin loaded oral nano bilosomes: Formulation optimization to preclinical assessment. Saudi Pharm J. 2021 Mar;29(3):269–79. doi: 10.1016/j.jsps.2021.02.003.
    [Google الباحث العلمي]
  37. Ali SK, Al-Akkam EJ. Effects of different types of bile salts on the physical properties of ropinirole-loaded. Bilosomes. Al-Rafidain J Med Sci. 2023;5:134–42. doi: 10.54133/ajms.v5i.176.
    [Google الباحث العلمي]
  38. Ali SK, Al-Akkam EJ. Bilosomes as soft nanovesicular carriers for ropinirole hydrochloride: Preparation and in-vitro characterization. Iraqi J Pharm Sci. 2023;32(Suppl.):177–87. doi: 10.31351/vol32issSuppl.pp177-187.
    [Google الباحث العلمي]
  39. Elkomy MH, Alruwaili NK, Elmowafy M, Shalaby K, Zafar A, Ahmad N, et al. Surface-modified bilosomes nanogel bearing a natural plant alkaloid for safe management of rheumatoid arthritis inflammation. Pharmaceutics. 2022 Mar 3;14(3):563. doi: 10.3390/pharmaceutics14030563.
    [Google الباحث العلمي]
  40. Parashar P, Rana P, Dwivedi M, Saraf SA. Dextrose modified bilosomes for peroral delivery: Improved therapeutic potential and stability of silymarin in diethylnitrosamine-induced hepatic carcinoma in rats. J Liposome Res. 2019 Sep;29(3):251–63. doi: 10.1080/08982104.2018.1551408
    [Google الباحث العلمي]
/content/journals/10.5339/jemtac.2024.absc.17
Loading
/content/journals/10.5339/jemtac.2024.absc.17
Loading

جارٍ تحميل البيانات والوسائط...

الموضوعات الرئيسية bilosomesgastrointestinal tract and oral drug delivery

الأكثر اقتباسًا لهذا الشهر Most Cited RSS feed

هذه الخانة مطلوبة
يُرجى إدخال عنوان بريد إلكتروني صالح
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error